TRIM2

Across TCGA pan-cancer cohorts, TRIM2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TRIM2 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TRIM2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TRIM2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, UCEC, and CCRCC are the cancer types where TRIM2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.655	0.281	.001	40	view →
UCEC	OS	Tertile	All	1.000	0.781	.004	30	view →
CCRCC	OS	Quartile	III,IV	1.000	0.613	.013	17	view →
GBM	OS	Quartile	All	0.223	0.709	.002	6	view →
OV	DFS	Median	All	0.592	0.884	.017	4	view →
LUAD	OS	Tertile	II,III,IV	0.746	0.426	.021	4	view →
LSCC	OS	Median	II,III,IV	1.000	0.905	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TRIM2–PDAC (DFS)

Open the PDAC breakdown →